Sensorion SA (ALSEN)

Overview

Sensorion SA, headquartered in Montpellier, France since its incorporation in 2009, stands at the forefront of biotechnological advancements with a specialized focus on developing therapeutic solutions for inner ear disorders. This innovative company has embarked on the mission of advancing drug candidates through various stages of clinical trials, with the ultimate goal of restoring, treating, and preventing disorders related to the inner ear. Utilizing cutting-edge science and research, Sensorion SA has made significant strides in understanding and combatting these health challenges, positioning itself as a pioneer in the field of otology within the biotech industry.

Products and Services

Sensorion SA's product pipeline is rich with promising drug candidates, each targeting a different aspect of inner ear health. This diverse portfolio underlines the company's comprehensive approach to tackling the complex challenges of ear disorders.

• SENS-401 SSNHL

Having completed Phase 2 clinical trials, SENS-401 SSNHL emerges as a groundbreaking treatment option for Sudden Sensorineural Hearing Loss (SSNHL). This condition, characterized by an abrupt loss of hearing, typically in one ear, has had limited treatment options until now. Sensorion's initiative through SENS-401 SSNHL demonstrates the potential for significant advancements in treating this debilitating condition.

• SENS-401 CIO

Currently in Phase 2 clinical trials, SENS-401 CIO specifically addresses Cisplatin-Induced Ototoxicity. Cisplatin, a commonly used chemotherapy drug, can have severe side effects including irreversible hearing loss. Sensorion SA is exploring SENS-401 CIO as a potential preventative treatment to protect patients from these ototoxic effects, offering hope to those undergoing cancer treatment.

• SENS-401 Cochlear

This drug candidate, also in Phase 2 clinical trials, is tailored for hearing preservation after cochlear implantation. The surgery, while beneficial for many, can sometimes damage residual hearing. SENS-401 Cochlear aims to mitigate such damage, potentially revolutionizing the approach to cochlear implantation and preserving the quality of life for recipients.

• OTOF-GT (SENS-501)

SENS-501 represents Sensorion’s venture into gene therapy with its completion of Phase 1 clinical trials. This program is designed to restore hearing in individuals living with Otoferlin deficiency, a genetic condition that can result in profound deafness. Through gene therapy, SENS-501 might offer a transformative cure for this genetic form of hearing loss, underscoring the innovative edge of Sensorion’s research and development.

• GJB2-GT

In the pre-clinical trial stage, GJB2-GT targets another genetic avenue for hearing restoration. This program focuses on mutations in the GJB2 gene, a common cause of genetic hearing loss. By addressing this specific genetic mutation, GJB2-GT could provide a targeted therapy with the potential to restore hearing in affected individuals, marking yet another step forward in the fight against genetic hearing loss.